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The Mig-10/RIAM/lamellipodin (MRL) family member
Rap1-GTP-interacting adaptor molecule (RIAM) interacts with
active Rap1, a small GTPase that is frequently activated in
tumors such as melanoma and prostate cancer. We show here
that RIAM is expressed in metastatic human melanoma cells
and that both RIAM and Rap1 are required for BLMmelanoma
cell invasion. RIAM silencing in melanoma cells led to inhibi-
tion of tumor growth and to delayedmetastasis in a severe com-
bined immunodeficiency xenograftmodel.Defective invasionof
RIAM-silenced melanoma cells arose from impairment in per-
sistent cell migration directionality, which was associated with
deficient activation of a Vav2-RhoA-ROCK-myosin light chain
pathway. Expression of constitutively active Vav2 and RhoA in
cells depleted forRIAMpartially rescued their invasion, indicat-
ing that Vav2 and RhoA mediate RIAM function. These results
suggest that inhibition of cell invasion in RIAM-silenced mela-
noma cells is likely based on altered cell contractility and cell
polarization. Furthermore, we show that RIAM depletion
reduces 1 integrin-dependent melanoma cell adhesion, which
correlates with decreased activation of both Erk1/2 MAPK and
phosphatidylinositol 3-kinase, two central molecules control-
ling cell growth and cell survival. In addition to causing inhibi-
tion of cell proliferation, RIAM silencing led to higher suscepti-
bility to cell apoptosis. Together, these data suggest that
defective activation of these kinases in RIAM-silenced cells
could account for inhibition of melanoma cell growth and that
RIAMmight contribute to the dissemination ofmelanoma cells.
Rap1 belongs to the Ras family of small GTPases, which are
molecular switches that couple extracellular signals with a vari-
ety of cellular responses, such as cell proliferation and survival,
cell adhesion, and cell polarity (1–3). Rap1 activation is regu-
lated by guanine-nucleotide exchange factors, which stimulate
exchange of bound GDP by GTP, and by GTPase-activating
proteins, which promote GTP hydrolysis (4). The GTP-associ-
ated form of Rap1 is responsible for interaction with its effec-
tors, which then transmit the signaling necessary to generate
cell responses.
Rap1-GTP-interacting adaptor molecule (RIAM)3 is an
effector protein for Rap1 that belongs to the MRL (Mig-10/
RIAM/Lamellipodin) family of adaptor proteins (5). RIAM
contains an N-terminal coiled-coil region, a central Ras associ-
ation, and pleckstrin homology domains, a C-terminal region
rich in prolines, aswell as several FPPPmotifswith the potential
of interacting with ENA-VASP proteins. RIAM is broadly
expressed, and it was first characterized as a molecule that pro-
motes Rap1-dependent1 and2 integrin activation onT lym-
phocytes (5). Subsequent work demonstrated that Rap1-RIAM
association favors talin targeting to the plasma membrane
through direct talin interaction with an N-terminal segment of
RIAM, a process that contributed to integrin activation (6, 7).
Furthermore, RIAM co-localizes with talin in lamellipodia (6),
representing a mechanism that could help to localize activated
integrins at these cell membrane protrusions. In addition,
recent data indicated that an MRL ortholog in Drosophila
called pico is required for tissue growth (8), therefore widening
the functional potential of MRL proteins in the control of dif-
ferent cellular responses.
RIAM also regulates T cell receptor-mediated signaling.
RIAM is recruited to immunological synapses during T cell-
antigen presenting cell interactions (9). Notably, the T cell
kinases ZAP-70, Fyn, and Lck can associate to RIAM and pro-
mote its tyrosine phosphorylation (10). Moreover, RIAM
silencing leads to impairment in Ras-dependent signaling and
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to defective translocation of phospholipase C-1 to the actin
cytoskeleton, resulting in inhibition of T cell activation (10).
Rap1 was shown to be activated in human melanoma cell
lines andmetastatic melanoma tissue, and it was proposed that
its activationmight controlmelanoma cell adhesion andmigra-
tion (11). Similarly, Rap1 activation correlates with high meta-
static potential in prostate cancer cell lines, which was associ-
ated with a decrease in the expression of Rap1GAP (12).
Examination of the cancer transcriptome profiles from the
Oncomine database reveals that RIAM mRNA is found in a
significant proportion ofmetastaticmelanoma samples. There-
fore, the potentially expressed RIAM protein might regulate
tumor cell motility upon binding to activated Rap1. Here, we
show that RIAMprotein is expressed in humanmetastaticmel-
anoma tissue and in melanoma cell lines, and we have used
highly invasive human melanoma cell lines as models to study
the role of RIAM in melanoma cell invasion. The results indi-
cated that RIAM is required duringmelanoma cell invasion and
that it controls melanoma cell growth and metastasis in an in
vivo xenograft model.
EXPERIMENTAL PROCEDURES
Cells, Antibodies, and Reagents—The human melanoma cell
line BLMwas cultured as described previously (13). Anti-RIAM
antibodies have been reported earlier (5); anti-Vav2 antibodies
were from Dr. Xose´ Bustelo (Centro de Investigacio´n del
Ca´ncer, Salamanca); control P3X63 and Lia1/2.1 integrin
anti-1 were from Dr. Francisco Sa´nchez-Madrid (Hospital de
la Princesa, Madrid, Spain), and 15/7 anti-1 was from Dr.
Ronen Alon (Weizmann Institute of Science, Rehovot, Israel).
Anti-CXCR4 was from R&D Systems (Minneapolis, MN), and
Rap1, PARP, RhoA, phosphotyrosine, andMyc 9E10 antibodies
were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
-actin, anti-talin, anti-HA, and anti-His were from Sigma;
anti-Erk1/2, anti-phospho-Erk1/2, anti-Akt, anti-phospho-Akt
(Ser-473), anti-phosphomyosin phosphatase (Thr-696), anti-
H-Ras, and anti-cleaved caspase-3 (Asp-175) were from Cell
Signaling Technology (Danvers, MA); anti-procaspase-3 was
from BD Biosciences, and anti-MLC antibodies were from
Invitrogen. Anti-human melanoma HMB-45 was from Dako
(Glostrup, Denmark). CXCL12 was purchased from R&D Sys-
tems; EGF and IGF-1 were from PeproTech (London, UK);
fibronectin was from Roche Diagnostics, and collagen I and
cisplatin were from Sigma.
Vectors, RNA Interference, Transfections, and PCR—HA-
fused pcDNA3.1 vectors coding for wild type and constitutively
active Rap1 (G12V) were from The Missouri S&T cDNA
Resource Center (Rolla, MO). To obtain BLM cells stably
overexpressing RIAM, its cDNA (5) was cloned into
pcDNA3.1-Myc or pcDNA4MaxC-His vectors. Cells were
either electroporated with pcDNA3.1-RIAM-Myc or co-trans-
fected with pcDNA4MaxC-RIAM-His and pBabe-puro vectors
using Lipofectamine (Invitrogen) or jetPrime (PolyPlus,
Illkirch, France). Transfectants were selected and maintained
in the presence of G418 or puromycin, respectively. Vectors
coding for GFP-fused forms of wild type RhoA and Vav2 and
activated V14-RhoA and Vav2 have been reported (14). To
interfere with Rap1 expression we used the following siRNAs:
siRap1A.1 sense strand, GAUAGAAGAUUCCUACA-
GAdTdT; siRap1A.2 sense strand, AUCAUGUCUGCUGCU-
CUAGdTdT, or a pSuper-Rap1 shRNA vector based on the
Rap1A.1 siRNA sequence. siRNA for RIAM had the following
sequences: siRIAM 1 sense strand, GGAAGACUCUCUAU-
GAUAAdTdT; siRIAM 2 sense strand, GGACAACCUUUUC-
GAGAAAdTdT; and siRIAM 3 sense strand, CUAUGGGA-
CUCAGCAUAAAdTdT. Control siRNA was as described
previously (14). Cells were transfected with siRNAs using
X-tremeGENE (Roche Diagnostics) or with pSuper vectors
using Lipofectamine, and transfectants were tested in the dif-
ferent assays 48 h post-transfection. To detect RIAM expres-
sion by PCR, we used the primers 5-AAAGCGCCCACTGAC-
TATTG-3 and 5-CGTTGCCTCTCTTCTTTTGC-3 and
GoTaq DNA polymerase (Promega, Madison, WI). Human
GAPDH primers were as reported previously (13).
Lentiviral Gene Transfer and Animal Studies—pLL3.7 or
pLL3.7-shRIAM (5) vectors were used to obtain mock or
RIAM-silenced cells. Packaging was performed with HEK293T
cells, and viral supernatants were used to infect target cells that
were selected by cell sorting based on their GFP expression.
BALB/c SCID mice (Harlan, Indianapolis, IN) maintained
under specific pathogen-free conditions were employed for
xenograft studies. The Cientificas Ethics Committee of the
Consejo Superior de Investigaciones (Madrid, Spain) approved
the protocols used for experiments with mice. Mice were
injected subcutaneously in the lateral thoracic wall or intrave-
nously into the tail vein with 1 106 cells. Mice were inspected
daily for tumor growth and were killed when signs of respira-
tory stress were noted or when subcutaneous tumors reached
volumes between 1.5 and 2 cm3.
Invasion, Migration, and Adhesion Assays—Invasions across
Matrigel were done as established previously (13). The lower
compartments of chambers were filled with invasion medium
with orwithoutCXCL12, and invasive cellswere countedunder
amicroscope.Weperformedwoundhealing assays to study cell
migration. For this, 1-mm-wide wounds were done across con-
fluent cell monolayers on Matrigel-coated plates, and cultures
were incubated with or without CXCL12. For adhesion assays,
cells were labeled, as shown previously (15), and loaded in trip-
licate on 96-wells dishes (Costar, Cambridge, MA) coated with
fibronectin (8 g/ml) or collagen I (1–2 g/ml). Cells were
allowed to adhere, and following washing to remove unbound
cells, adhesion was quantified using a fluorescence analyzer
(POLARstar Galaxy; Offenburg, Germany).
Time-lapse Video Microscopy—Time-lapse analyses in
migration experiments were performed using chemotaxis
chambers (Ibidi, Martinsried, Germany) coated with Matrigel,
using the described method (16). CXCL12 was added in the
upper reservoir, and cell movement was tracked (2min for each
frame for 5 h) using a Live Cell Imaging microscope. Euclidean
mean distance was assessed with ImageJ software. For protru-
sion dynamics, paxillin-dsRed2-transfected cells were seeded at
5000 cells/well on fibronectin-coated (10 g/ml) glass-bottom
96-well plates. Cells were allowed to attach for 45 min, and
subsequently, images were taken every 10 min using a Nikon
A1R confocal microscope with a60 oil-immersion objective.
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Three-dimensional Gel Cultures, Confocal Microscopy, and
Immunohistochemistry—Rat tail collagen I (3.6 mg/ml) (Milli-
pore, Billerica, MA) was equilibrated with NaHCO3/NaOH
buffer to meet neutral pH, and immediately mixed with 10
DMEMand cells to have a finalmixture of 0.8mg/ml collagen I,
2DMEM, 2.5%FBS suspension (2 105 cells/ml). 20l drops
of this mixture were allowed to polymerize at 37 °C, and result-
ing gels were covered with DMEM/serum and incubated for
24–72 h. Cells were stained with DAPI (0.3 M) and imaged
using a Leica TCS-SP2-AOBS-UV and Nikon A1R confocal
microscope with 63 water-immersion and 60 oil-immer-
sion objectives. The Ethical Committee at Hospital Universita-
rio Gregorio Maran˜o´n approved the protocols and process
involving human melanoma samples. For immunohistochem-
istry, melanoma metastases from lymph nodes were immedi-
ately frozen, and acetone-fixed 4-m-thick sections were first
incubated with 10% nonimmune goat serum. Samples were
then incubated for 1 h at 23 °Cwith the appropriated antibodies
or isotype-matched control antibodies. All antibodies were first
tested for reactivity on lymphoid tissue and skin. The slides
weremounted using an aqueous permanentmountingmedium
(DAKO). Confocal microscopy images were captured using a
Leica SP2-AOBS confocal microscope.
Immunoprecipitation, Immunoblotting, and GTPase Assays—
For immunoprecipitation, melanoma cells were lysed (17) and
extracts incubated with antibodies followed by specific cou-
pling to protein A- or G-Sepharose beads, as established previ-
ously (18). After SDS-PAGE, proteins were subjected to immu-
noblotting with primary antibodies, followed by incubation
with horseradish peroxidase-conjugated secondary antibodies
and detection with chemiluminescent substrate (Pierce). Rap1,
RhoA, and H-Ras GTPase assays were performed on cells incu-
bated in suspension with CXCL12 (13). Upon cell lysis, aliquots
from extracts were kept for total lysate controls, and the
remaining volume was incubated with GST-Ral-GDS (for
active Rap1), GST-C21 (for active RhoA), or GST-Raf-RBD (for
active H-Ras) fusion proteins in the presence of glutathione-
agarose beads. Eluted proteins were subjected to immunoblot-
ting with Rap1, RhoA, or H-Ras antibodies.
Cell Proliferation andCytotoxicity Assays—Cell proliferation
was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assay. Cells (8 103/well) were seeded
in 96-well plates, incubated for 16 h, and subsequently stained
with 0.5 mg/ml thiazolyl blue tetrazolium bromide (Sigma).
Resulting formazan was resuspended with 200 l of DMSO/
well, and absorbance was read at 540 nm. Soft agar assays were
performed as described previously (19). For cytotoxicity assays,
cells were treated with cisplatin or H2O2; nonadherent cells
were removed, and monolayers of surviving cells were fixed
with paraformaldehyde. Upon staining with crystal violet, cells
were washed and resuspended in acetic acid (33%), and absor-
bance was determined at 570 nm.
Statistical Analyses—Data were analyzed by one-way analy-
sis of variance followed by Tukey-Kramer multiple compari-
sons. In both analyses, the minimum acceptable level of signif-
icance was p 0.05.
RESULTS
Rap1andRIAMAreRequired for Invasion ofMelanomaCells—
Rap1 in the highly metastatic human BLM melanoma cell line
was found to be basally activated, but its activation was further
increased upon exposure to CXCL12 (Fig. 1A), a chemokine
that promotes melanoma cell invasion following binding to its
receptor CXCR4 (13, 20). Rap1 silencing with two different
siRNAs and with shRap1 led to defective invasion across the
three-dimensional Matrigel layers in response to CXCL12 (Fig.
1, B and C). Conversely, cells transfected with constitutively
active Rap1 exhibited an increase in invasion compared with
Rap1 WT or mock counterparts (Fig. 1D). These data indicate
that the chemokine-promoted melanoma cell invasion needs
Rap1 function.
Earlier work demonstrated that GTP-bound active Rap1
interacts with RIAM (5). To study if RIAM was expressed in
human melanoma cells, we performed immunohistochemistry
on metastatic melanoma surgical specimens using anti-RIAM
antibodies and antibodies to the specific melanoma marker
HMB-45. The analyses revealed low to medium RIAM expres-
sion onmelanoma cells frommacroscopically infiltrated lymph
nodes (7 of 8 cases) (Fig. 2A; and supplemental Fig. S1), as well
as on stromal components of the tumor microenvironment.
The pattern of cellular RIAM distribution and localization
inside the tumors was heterogeneous. Thus, some melanoma
cells displayed a predominant cytoplasmic localization of
RIAM, whereas in other cells RIAM was also found on cell
membrane regions. Furthermore, melanoma cells positive for
RIAM expression were detected across the tumoral mass but
also on the invasive borders of the tumors. In addition to its
expression onmetastatic melanoma tissue, RIAMwas found to
be expressed on themelanoma cell lines BLM,MeWo, SK-Mel-
147, and SK-Mel-173, whereas its expression was undetectable
in Mel57 cells (supplemental Fig. S2A). Pulldown assays using
the GST-Ral-GDS fusion protein showed that RIAM binds to
Rap1-GTP in chemokine-stimulated BLMmelanoma cells (Fig.
2B).
To investigate if RIAM is needed formelanoma cell invasion,
BLM cells were infected with lentiviral vectors designed for
stable RIAM silencing (5). Two different transfectants, D11 and
F7, displayed between 80 and 90%decrease in RIAMexpression
comparedwithmock transfectants (Fig. 2C, top panel; and sup-
plemental Fig. S2B). Control experiments revealed no altera-
tions in CXCR4 or 1 integrin expression levels in these trans-
fectants (data not shown). Invasion in response to CXCL12was
blocked in D11 and F7 cells (Fig. 2C, bottom panel), as well as in
an additional RIAM-depleted subline, F8-luc, engineered to
express luciferase for future in vivo bioluminescence studies
(supplemental Fig. S2C). Moreover, transient knockdown of
RIAM by siRNA RIAM 2 and 3 led to strong inhibition of inva-
sion toward CXCL12, whereas partial RIAM depletion by
siRNA RIAM 1 resulted in a modest inhibition of invasiveness
(Fig. 2D). To test if defective invasion shown by RIAM-silenced
BLM cells could also be detected using stimuli other than
CXCL12, we analyzed cell invasion toward serum. Results
revealed that D11 stable transfectants as well as cells trans-
fected with RIAM siRNA had a blockade of invasiveness in
Rap1 and RIAM inMelanoma Cell Invasion
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response to serum (supplemental Fig. S2D). Further support for
the important role of RIAM in melanoma cell invasion came
from experiments using BLMcells overexpressingHis- orMyc-
tagged RIAM, which exhibited a remarkable up-regulation of
invasiveness compared with mock transfectants (Fig. 2E).
Importantly, defective invasion of RIAM-depleted D11 cells
was rescued by RIAM-His overexpression (Fig. 2F), indicating
that deficient invasion was specifically due to RIAM knock-
down. Transfection of RIAM-His in Rap1 siRNA transfectants
reversed their defective invasion, whereas active Rap1 was
unable to recover the impairment in invasion displayed by
siRIAM transfectants (Fig. 2G). These results strongly suggest
that RIAM acts downstream of Rap1 during chemokine-stim-
ulated melanoma cell invasion. To analyze if RIAM silencing in
another RIAM-positive, highly invasive melanoma cell line led
to deficient invasion, we used MV3 cells, which displayed
impaired invasiveness following RIAM depletion (supplemen-
tal Fig. S2E). The defect in the invasion of RIAM-silenced cells
was not due to alterations in secretion or expression ofMMP-2
or MT1-MMP, two metalloproteinases involved in CXCL12-
promoted melanoma cell invasion (14), or of MMP-9 (supple-
mental Fig. S2F). Together, these data indicate that melanoma
cell invasion requires activation of the Rap-1-RIAM signaling
pathway.
Directional Persistence of Migration Is Defective in RIAM-
silenced Melanoma Cells—In addition to their deficient inva-
sion across three-dimensional Matrigel layers, wound closure
assays showed that RIAM-depleted BLM cells displayed a sig-
nificant inhibition ofmigration in the presence of CXCL12 (Fig.
3A). To investigate the mechanisms behind their impaired
migration, we first analyzed migration by time-lapse micros-
copy in chemotaxis chambers. Mock cells displayed Euclidean
mean distance migratory values that were more than 2-fold
higher than those from RIAM knockdown transfectants, indi-
cating that RIAMdepletion affected persistentmigration direc-
tionality (Fig. 3B; see also supplemental Videos 1 and 2). A close
examination at membrane protrusions during migration
revealed that although mock cells exhibited dynamic ruffle and
filopodia extensions, cells depleted for RIAM showed periodic
waves of lamellae protrusions that lead to a rounded morphol-
ogy (Fig. 3C; and supplemental Videos 3 and 4).
Activation of Vav2/RhoA-dependent Signaling Is Impaired in
RIAM-depleted Melanoma Cells—The deficiency in persistent
migration directionality of RIAM-silenced cells might reflect a
defective cell polarization, which could arise from alterations in
cell contractility (21). As stress fiber formation and contractility
require Rho GTPase-dependent activation of theMLC of myo-
sin II (22, 23), we examined whether activation of RhoA and
FIGURE 1. CXCL12-promoted melanoma cell invasion is dependent on Rap1. A, BLMmelanoma cells were incubated with or without CXCL12 and subse-
quently subjected to Rap1GTPase assays.Numbersbelow the gel represent densitometer analyses in arbitrary units. B, BLM cells were transfectedwith control
(Ctrl) or the indicated Rap1A siRNA, and transfectants were analyzed by immunoblotting with anti-Rap1 antibodies (left panel) or tested in invasion assays
across Matrigel in response to CXCL12 (right panel). C, cells were transfected with pSuper or pSuper-Rap1A vectors, and transfectants were analyzed by
immunoblotting (left panel) or subjected to invasion assays (right panel).D,BLMcellswere transfectedwithwild type Rap1 (Rap1wt), constitutively active Rap1
(Rap1 CA), or empty vectors (Mock), and transfectants were analyzed by Western blotting with anti-Rap1 or anti-HA antibodies (left panel) or subjected to
invasion assays acrossMatrigel (right panel). ***, invasionwas significantly inhibited, p 0.001; **, p 0.01, or *, p 0.05. All invasion experiments were done
with duplicate samples. (B, n 4; C, n 3). Invasionwas up-regulated comparedwith invasion bymock cells, p 0.01 (n 2). Anti--actin antibodies were
used to control protein loading in Western blots.
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MLC may be altered in RIAM-silenced cells. We first ana-
lyzed phosphorylation of Vav2, which is a guanine-nucle-
otide exchange factor activator molecule for RhoA (24, 25).
Both Vav2 tyrosine phosphorylation and Vav2 binding to
RhoA following CXCL12 stimulation were defective in D11
transfectants compared with mock counterparts (Fig. 4A),
which were associated with impairment of RhoA activation
(Fig. 4B). Instead, the degree of tyrosine phosphorylation of
p190RhoGAP, a GTPase-activating protein for RhoA, was sim-
ilar in mock and D11 cells (data not shown). RhoA activates its
downstream effector ROCK, which in turn phosphorylates
MLC (23). As a readout of ROCK activity, we determined the
phosphorylation at Thr-696 of one of its downstream targets,
the myosin phosphatase subunit (MYPT1). The results showed
a deficient MYPT1 phosphorylation in response to CXCL12 in
RIAM-knockdown cells (Fig. 4C). Once phosphorylated, myo-
sin II assembles intomyosin filaments and associates with actin
filaments for generation of contractile stress fibers that are
needed for cell migration (26). We found that the defect in
RhoA-ROCK activation in D11 cells was associated with a
decrease in MLC phosphorylation levels (Fig. 4D), suggesting
that activation of a Vav2-RhoA-ROCK-MLC pathway is
impaired in RIAM-silenced melanoma cells.
To determine whether altered Vav2-RhoA activation in
RIAM knockdown cells accounted for inhibition of melanoma
cell invasion, we expressed constitutively active forms of Vav2
and RhoA (Vav2 CA and RhoA CA, respectively) in mock and
D11 cells, and we tested transfectants in invasion assays. Over-
expression of Vav2 CA in D11 cells resulted in rescue of RhoA
activation as well as to a partial recovery of invasion (Fig. 4E).
Furthermore, overexpression of RhoA CA in D11 cells also led
to a partial rescue of invasion compared with the same cells
transfected with RhoA WT (Fig. 4F). Similarly, F8-Luc cells
transfected with RhoA CA displayed higher invasion than the
same cells transfectedwith RhoAWT forms (supplemental Fig.
S3). These results indicate that impaired invasiveness shown by
RIAM-silenced BLMmelanoma cells involves a defect in Vav2-
RhoA-ROCK-MLC activation.
Association between Talin and 1 Integrin and 1-mediated
Adhesion Are Impaired in RIAM-depleted Melanoma Cells—
Analyses of cell distribution of endogenous and transfected
RIAMrevealed that it was found at the edges of cell protrusions,
usually showing a patchy distribution, as well as diffusely in the
cytoplasm of BLM cells (supplemental Fig. S4A). Furthermore,
RIAM-His co-precipitated with talin in these cells (supplemen-
tal Fig. S4B), in agreement with RIAM-talin association previ-
ously reported in other cell types (7). Notably, RIAM silencing
led to defective association of talin with the integrin 1 subunit
(Fig. 5A). As also shown before (27), talin co-precipitation with
anti-1 antibodies was specific, as it was not detected in talin
siRNA transfectants, and these antibodies co-precipitated the
counterpart 4 integrin subunit but not PARP (supplemental
Fig. S5). Moreover, RIAM-His expression in RIAM-depleted
D11 cells led to recovery of talin 1 association (Fig. 5B), indi-
cating that the assembly between these proteins requires
RIAM. Linked to defective talin1 association inRIAM-knock-
down cells, they displayed a decrease in 1 integrin-dependent
attachment to fibronectin and type I collagen compared with
control transfectants (Fig. 5, C and D, left panels). On the con-
trary, RIAM overexpression resulted in up-regulated cell adhe-
sion to fibronectin (Fig. 5C, right panel). As 3 integrin expres-
sion is negligible in BLM melanoma cells (data not shown),
together with the blockade of cell attachment by anti-1 mAb,
our adhesion results clearly reflect the activity of 1 integrins.
Given that talin1 association is an event that correlateswith
integrin activation (28) and that this association is impaired in
RIAM-silenced cells, we tested the binding of 15/7, an anti-1
antibody that detects high affinity 1 integrin conformations
(29), as an indication of the degree of integrin activation in these
cells. Binding of 15/7 mAb was moderately reduced in D11
transfectants comparedwithmock counterparts (supplemental
Fig. S6A). Flow cytometry control experiments showed that
mock and D11 cells retained similar degrees of 15/7mAb bind-
ing upon exposure to Mn2, a positive activator of integrin
affinity. To study if reduced 15/7 mAb binding to RIAM-de-
pleted cells could reflect possible changes in integrin ligand
binding, we used biotin-labeled fibronectin in soluble binding
experiments. The results showed minimal and nonstatistically
significant differences in fibronectin binding between mock
and D11 cells (supplemental Fig. S6B). In addition, confocal
microscopy together with software-assisted custom-patch
morphology analyses showed that there were no gross altera-
tions in the degree of 1 integrin clustering in D11 cells com-
pared with mock counterparts (supplemental Fig. S6C). These
results suggest that no differences in 1 integrin avidity for
their ligands exist between both cells. Together, these data indi-
cate that RIAM depletion affects talin 1 association, which
leads to alterations in 1 affinity conformations but with min-
imal effects on ligand binding.
RIAM-silenced Melanoma Cells Have Decreased Erk1/2 and
Akt Activation—As also reported in T cells (10), knockdown of
RIAM inmelanoma cells led to inhibition of Ras activation, and
FIGURE2.RIAMis required formelanomacell invasion.A, immunohistochemical analysis of RIAMexpressiononmelanoma lymphnodemetastasis. Sections
were stainedwith themelanoma-specificmarker HMB-45 (tumor) orwith anti-RIAMantibodies orwithDAPI to visualize nuclei. Sample 82 is shown. Additional
analyses of melanoma specimens are shown in supplemental Fig. S1. B, lysates from BLM cells exposed for 15 min to CXCL12 were incubated with GST or
GST-Ral-GDS, and bound Rap1 and RIAM were detected by immunoblotting. C, expression of RIAM in untransfected BLM cells, and in Mock and stable RIAM
knockdown transfectants (D11 and F7), was analyzed by immunoblotting with anti-RIAM antibodies (top panel). Numbers below the gel represent densitom-
eter analyses in arbitrary units. Bottompanel, transfectantswere tested in invasion assays acrossMatrigel.D,BLMcellswere transfectedwith control orwith the
indicated RIAM siRNA, and transfectants were analyzed by immunoblotting (top panel) or subjected to invasion assays (bottom panel). E, BLM cells were
transfected with His- or Myc-tagged RIAM vectors, and transfectants were analyzed by immunoblotting to determine RIAM-His or RIAM-myc expression (left
panel) or subjected to invasion assays (right panel). F,mock and D11 cells were transfected with control or RIAM-His vectors, and their invasion to CXCL12 was
comparedwith that ofmock cells.G,BLMcellswere transfectedwith the indicated siRNA togetherwith Rap1CA, RIAM-His, ormock vectors. Transfectantswere
analyzed by immunoblotting (top panel) or tested in invasion assays (bottompanel). (C, n 5;D, n 3; E, n 3; F, n 2;G, n 2.) ***, invasionwas significantly
inhibited,p0.001; **,p0.01;, invasionwasup-regulated comparedwith invasionbymock transfectants,p0.001;,p0.01;,p0.05. Anti--actin
antibodies were used to control protein loading in Western blots.
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exposure to CXCL12 could not recover the activation to the
levels shown by mock cells (Fig. 6A). These results suggested
that Ras downstream signaling could be affected due to RIAM
silencing. Indeed, activation of both Erk1/2 MAPK and the
phosphatidylinositol 3-kinase (PI3K) downstream effector Akt
following 1 integrin-dependent adhesion to fibronectin and
type I collagen was lower in RIAM-depleted BLM melanoma
transfectants than inmock counterparts (Fig. 6,B andC). Nota-
bly, Erk1/2 MAPK activation in RIAM knockdown cells was
rescued following transfection of RIAM-His (Fig. 6D). These
results indicate that RIAM silencing in melanoma cells affects
activation of1 integrin-mediated outside-inmolecular signal-
ing that regulates cell growth and survival, such as Erk1/2
MAPK and PI3K activation.
Growth factor receptors cooperate with integrins to stimu-
late and/or sustain the activation ofMEK-Erk1/2 and PI3K-Akt
FIGURE 3. Directional persistence of migration is deficient in RIAM-silenced melanoma cells. A, transfectants in culture were tested in wound healing
assays in thepresenceofCXCL12 (50ng/ml). A representative result fromthreeexperiments is shown.B, transfectantswere subjected to time-lapsemicroscopy
experiments on Matrigel. CXCL12 (150 ng/ml) was added on the top reservoir of chambers, and migration of individual cells (n  15) was tracked and
represented in micrometers (x and y axis) using a common starting point in the middle of the graph. Shown is a representative result of three independent
experiments. EMD, Euclidean mean distance. C, cells were transfected with DsRed-paxillin, and membrane protrusions were analyzed for the indicated times
by time-lapse microscopy. Shown are two representative individual cells from each mock and D11 transfectant.
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FIGURE4. Impaired invasionofRIAM-silencedmelanomacells involvesdefectiveVav2-RhoA-ROCK-MLCactivation.A,mockorD11cellswere incubated
for the indicated times with CXCL12 and subjected to immunoprecipitation (IP) with anti-Vav2 antibodies, followed by immunoblotting with the indicated
antibodies.Numbers below the gel represent densitometer analyses in arbitrary units showing Vav2 tyrosine phosphorylation levels. B–D, cells were tested for
GTPase assays to detect active RhoA (B) or analyzed byWestern blotting for phospho-MYPT1 (C) or for phospho-MLC or total MLC expression (D). E,mock and
D11 cells were transfected with GFP-fusedwild type (wt) or constitutively active (CA) forms of Vav2, and transfectants were analyzed by immunoblotting with
anti-Vav2 antibodies (top panel) or subjected to RhoA GTPase and invasion assays (middle and bottom panels, respectively). F, mock and D11 cells were
transfected with GFP-fused wild type (wt) or constitutively active (CA) forms of RhoA, and transfectants were analyzed by immunoblotting with anti-RhoA
antibodies (left panel) or tested in invasion assays (right panel). , invasions of D11-Vav2 CA or D11-Rho CA transfectants were significantly higher than
D11-Vav2 WT or D11-Rho WT cells, respectively, p 0.01.
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pathways (30). We therefore tested if the decreased activation
of these signaling pathways in RIAM-silenced melanoma cells
could be recovered by exposure to growth factors. Following
incubation with EGF, starved D11 cells displayed Erk1/2 and
Akt phosphorylation levels similar to those found inmock cells
(Fig. 6E, left panel). When cells were exposed to IGF-1, Akt
phosphorylation was comparable between mock and RIAM-
depleted cells, although Erk1/2 activation was only partially
recovered (Fig. 6E, right panel). These results strongly suggest
that Erk1/2 and PI3K-Akt activation through RIAM is integrin-
dependent and growth factor-independent.
Growth andMetastatic Properties of RIAM KnockdownMel-
anoma Cells—RIAM-silenced and mock melanoma cells were
inoculated into SCIDmice to follow their growth and dissemina-
tion. Between days 25 and 75 after subcutaneous inoculation with
mockcells, allmice (n13) displayed tumor volumesbetween1.5
and 2.0 cm3, whereas only 3 of 10 or 1 of 10 mice inoculated with
D11 or F7 cells, respectively, showed these tumor volumes (Fig.
7A). No subcutaneous tumor growth was detected in 60 and 90%
of mice inoculated with D11 and F7, respectively, up to day 125.
Three weeks after intravenous inoculation with mock mela-
noma transfectants, mice rapidly developed lung metastases,
and after 6 weeks there were no surviving mock animals (Fig.
7B). D11 and F7 mice had a significantly longer disease-free
period (5.5–8 weeks), which was linked to a prolonged survival
(Fig. 7B). Melanoma cells derived from lung metastases
retainedGFP expression and displayed invasiveness toMatrigel
comparable with their original transfectants (supplemental Fig.
S7, A and B), indicating that they retained their invasive prop-
erties during dissemination. Inhibition of in vivo tumor growth
shown by RIAM knockdown melanoma cells correlated with
abolishment in their capacity to form colonies in soft agar cul-
tures compared with mock cells (Fig. 7C). Furthermore, D11
and F7 cells displayed a reduction in cell proliferation, and con-
versely, cells overexpressing RIAM-His had higher prolifera-
tion rates than mock transfectants (Fig. 7D). Together, these
data indicate that RIAMexpression contributes to in vitroBLM
melanoma cell proliferation and confers growth andmetastatic
advantages to these melanoma cells in a xenograft model.
As inhibition of in vivo growth shown by RIAM-depleted
melanoma cells might also reflect apoptosis responses, we first
analyzed whether they have increased sensitivity to apoptosis-
inducing agents. As a model for induction of cell apoptosis, we
used cisplatin, a pro-apoptotic DNA-alkylating agent used in
2
FIGURE 5. RIAM-silenced melanoma cells have reduced talin 1 integrin association and defective 1 integrin-mediated adhesion. A, transfectants
were subjected to immunoprecipitation (IP) with control (Ctr) or Lia 1/2.1 anti-1 antibodies, followedby immunoblottingwith anti-talin or anti-1 antibodies.
B,mock or D11 cells were transfectedwith control or RIAM-His vectors and subjected to immunoprecipitation andWestern blotting as in A. Total talin loading
is also shown.CandD, transfectantswere tested in adhesionassays (10min, 37 °C) to fibronectinor type I collagen, in thepresenceof control or Lia 1/2.1 anti-1
mAb. Basal adhesion to BSA is also displayed. ***, adhesion was significantly inhibited, p 0.001; **, p 0.01; or *, p 0.05; or stimulated , p 0.05 (n 4).
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the treatment of solid tumors (31). Cisplatin induced a dose-de-
pendent decrease in cell survival that was of significantly higher
extent in D11 and F7 than in mock cells (Fig. 8A, left panel).
This observation was associated with reduced levels of pro-
caspase-3 and with higher PARP cleavage in D11 transfectants
(Fig. 8A, right panel). In addition, D11 and F7 transfectants
were more susceptible than mock cells to apoptosis by the
hydroxyl radicals generated from excess H2O2 (Fig. 8B). Given
that melanoma cells invade across type I collagen-rich dermal
connective tissue layers, we embedded mock and D11 cells in
three-dimensional collagen I gels and performed caspase-3 stain-
ing and analyses of nuclei integrity as an indication of cell apopto-
sis. Staining ofD11 cellswith an antibody to cleaved caspase-3was
substantially stronger than inmock cells (Fig. 8C). Following 72 h
in the collagen gels, RIAM-silenced cells displayed a higher pro-
portion of compact/broken nuclei than mock cells (70 and 15%,
respectively), as well as increased Hoechst staining (supplemental
Fig. 8). These data indicate that cells depleted for RIAM have
increased susceptibility to apoptosis.
Finally, as p38 MAPK activation is linked to cell stress and
plays key roles in the control of cell proliferation and survival
(32), we assessed its phosphorylation levels in mock and RIAM
knockdown cells. The results showed that p38 MAPK was
phosphorylated to higher levels in D11 than inmock cells when
they were exposed to cisplatin (Fig. 8D).
DISCUSSION
We have used highly invasive human melanoma cell lines to
demonstrate that their invasion requires Rap1 and its binding
partner RIAM.We found that RIAM is expressed inmelanoma
cells in human metastatic tissue, although its expression was
not restricted tomelanoma cells, as other cells within the tumor
microenvironment also expressed RIAM. It is not known at
present whether RIAM expression on melanoma cells contrib-
utes to tissue invasion, or if its expression could be used as a
prognostic value, a hypothesis that will be next studied. Nota-
bly, RIAM silencing in melanoma cells led to inhibition of
FIGURE 6. RIAM-silenced melanoma cells have defective Erk1/2 and Akt activation. A, cells were incubated for the indicated times with CXCL12 and
subsequently subjected to Ras GTPase assays. B and C, transfectants were plated for the indicated times on fibronectin or collagen I, and following cell lysis,
extracts were subjected to Western blotting with antibodies to phospho-Erk1/2, Erk1/2, phospho-Akt, or Akt. D, mock and D11 cells were transfected with
control or RIAM-His vectors and subsequently analyzed by immunoblotting with phospho-Erk1/2 and Erk1/2 antibodies. E, transfectants were starved for 8 h
and subsequently incubated for the indicated times with EGF (10 ng/ml) or IGF-1 (100 ng/ml). Cells were then lysed and subjected to immunoblotting using
anti-Erk1/2 or anti-Akt antibodies.
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tumor growth and delayed metastasis in a SCID xenograft
model, suggesting that RIAM expression on melanoma cells
might indeed contribute to tumor progression.
Experiments to rescue the invasion of Rap1 and RIAM
siRNA transfectants indicated that RIAM acts downstream of
Rap1 for efficient cell invasion triggered by CXCL12. Defective
invasion of RIAM-silenced melanoma cells arose from impair-
ment in sustained cell migration directionality, whichwas asso-
ciated with inhibition in the activation of a Vav2-RhoA-ROCK-
MLC pathway. Furthermore, our results indicate that RIAM
depletion reduces 1-dependent melanoma cell adhesion, which
correlates with decreased activation of both Erk1/2 MAPK and
PI3K, two central molecules that control cell growth and cell sur-
vival. In addition, to inhibit cell proliferation, RIAM silencing led
to higher susceptibility to cell apoptosis.
BLM melanoma cell knockdown for RIAM displayed a pre-
dominant rounded morphology linked to impairment in the
acquisition of a polarized phenotype. Myosin II-based contrac-
tility generates the force needed for cell migration, and it con-
tributes to cell polarity and to persistent cell migration (21, 26,
33). In support for defective polarization in cells knocked down
for RIAM that display impaired migration is the finding that
they have deficient activation of the regulatory MLC compo-
nent of myosin II. The defect in MLC phosphorylation corre-
latedwith inhibition in the activation of theVav2-RhoA-ROCK
pathway, suggesting that altered stimulation of this pathway
accounts for impairment of MLC activation in these cells.
Importantly, expression of constitutively active Vav2 andRhoA
forms partially rescued invasion of RIAM-depleted melanoma
cells, indicating that Vav2 and RhoA mediate RIAM functions.
Therefore, the data suggest that inhibition of invasion in
RIAM-silenced cells involves altered contractility and cell
polarization due to deficient activation of a Vav2-RhoA-
ROCK-MLC pathway. The structural and functional connec-
FIGURE 7. RIAM silencing inmelanoma leads to inhibition of tumor growth and delayedmetastasis. A, SCIDmice were subcutaneously inoculated with
the indicated melanoma BLM transfectants. Data show the correlation between days post-inoculation and percentage of mice with tumors (left panel) or
tumor-freemice (right panel). B, shown are survival curves of SCIDmice intravenously inoculatedwith the indicatedmelanoma transfectants (***, survival was
significantly higher than mice inoculated with mock transfectants, p  0.001). C, displayed are representative fields of anchorage-independent colony
formation on soft agar (left panel), and quantification inmean colony numbers (right panel, n 3; duplicates). Only colonies larger than 50mwere counted.
D, cell proliferation was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (left panel). *, proliferation was inhib-
ited, p 0.05, or augmented; , p 0.001 (n 4). Right panel, cells (5 103) were cultured in complete medium for the indicated times and counted in
Newbauer chambers (n 3).
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tions of RIAM with this pathway are not known at present and
should be the subject of future studies. A possible explanation is
based on the fact that active Rap1 contributes to cell localiza-
tion of Vav2 (34). Therefore, it is tempting to speculate that a
Rap1-GTP/RIAMcomplexmight recruit Vav2 to the cellmem-
brane for subsequent Vav2 activation.
Recent work has reported that RIAMbinds talin, which facil-
itates the recruitment of talin to 3 integrin sites and subse-
quent activation of these integrins (6, 7, 35). We found that, in
addition to binding to Rap1, RIAM also associates with talin in
melanoma cells. Interestingly, RIAMdepletion led to a decrease
in talin 1 integrin association that was linked to a reduction in
1 integrin-dependent cell adhesion to fibronectin and colla-
gen I. The basis for this reduced adhesion is not known at pres-
ent, but it does not seem to involve gross differences in 1
clustering or 1 integrin activation between mock and RIAM-
silenced cells. A small but consistent decrease in the generation
of high affinity 1 conformations in RIAM-silenced cells was
detectedwith the 15/7 anti-1mAb. This is an observation that
might reflect the decrease in talin 1 association in these cells,
given that talin is a main protein controlling integrin activation
(28). As mentioned above, RIAM-knockdown cells display a
more rounded phenotype thanmock cells, conceivably because
of changes in the reorganization of the actin cytoskeleton,
which might affect adhesion strengthening, ultimately leading
to reduced cell adhesion. Therefore, our results suggest that as
a result of its talin-binding capacity, RIAM possibly regulates
the assembly of 1-dependent adhesive platforms that are
required for efficient cell adhesion.
The reduction in1-dependent adhesion of RIAMknockdown
cells is most likely the basis for the decreased activation of Erk1/2
and the PI3K downstream effector Akt, which are well known
downstream targets in outside-in signaling from integrins, involv-
ing at least cyclin D1 (30, 36). Ras represents an upstream candi-
date mediating integrin-dependent Erk1/2MAPK activation that
is regulated byRIAMactivity. Thus, it has beendemonstrated that
RIAM depletion in T cells results in failure of Ras-dependent
Erk1/2 activation in response to TCR stimulation (10). Indeed, we
found that RIAM-knockdownmelanoma cells have defective Ras
activation, strongly suggesting that this defect represents a mech-
anism responsible for the deficient Erk1/2 activation.
One of the possible mechanisms behind the defective growth
shown by RIAM-knockdown melanoma cells subcutaneously
inoculated intoSCIDmice couldbebasedondeficient stimulation
of 1 integrin-dependent outside-in signaling pathways such as
those controlled by Erk1/2 and PI3K, which are needed for cell
proliferation. The levels of Erk1/2 and Akt phosphorylation
detected in RIAM-depleted melanoma cells following incubation
with EGF or IGF indicate that Erk1/2 and PI3K-Akt activation
involving RIAM is integrin-dependent but growth factor-inde-
pendent, and again it reflects the important role of upstream
RIAM in the control of1 integrin-mediated outside-in signaling.
Our data suggest that when melanoma cells are in tissue culture
conditions, thereducedadhesionshownbyRIAM-depletedcells is
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likely sufficient to result in decreased Erk1/2 and Akt activation,
and only when large amounts of growth factors are exogenously
provided is activation rescued. In in vivo conditions, limited
growth factor supply and poor adhesion might lead to the
observed inhibition of growth of RIAM-silenced cells.
Concomitant with the inhibition of proliferation shown by
RIAM-silencedmelanoma cells, they also displayed an increase
in susceptibility to apoptosis than their mock counterparts.
Their higher apoptosis responses were detected in two-dimen-
sional cultured RIAM-depleted cells exposed to cisplatin, as
well as when they were embedded in three-dimensional type I
collagen gels, a condition that mimics connective tissue envi-
ronments that must be crossed during invasion of melanoma
cells. These responsesmight be a consequence of their defective
proliferation dependent on outside-in signaling from 1 integ-
rins. Although thev3 integrin has been shown to be involved
in melanoma cell survival (37, 38), it is unlikely that it plays a
role in BLM cell survival, given that these cells express only
background levels of this integrin (data not shown). Therefore,
a decrease in proliferation and higher sensitivity to apoptosis of
RIAM-depleted melanoma cells might contribute to inhibition
of tumor growth of subcutaneously injected cells.
When RIAM-silenced melanoma cells were intravenously
inoculated, we detected significantly longer survival of SCID
mice, associated with delayed latency of lung dissemination,
than in those mice injected with mock cells. Based on the
impaired cell invasiveness displayed by RIAMknockdown cells,
a delay in the latency could reflect a defective lung homing and
invasion capacity of these cells that could retard the initial steps
of lung colonization. Alternatively, melanoma cell arrival to
lungs might be only modestly affected by RIAM depletion, and
the extended survival of mice might reflect the reduction of
melanoma cell growth because of RIAM silencing. Amore per-
missive lung environment compared with that of primary skin
tumor could later favor the growth of RIAM-depleted mela-
noma cells involving lung growth factors. Altogether, these
results indicate that RIAM contributes to cell growth and
metastasis of BLM melanoma cells. Importantly, the Drosoph-
ilaMRLprotein ortholog pico is required for tissue growth, and
its silencing leads to reduced cell division rates (8), thus stress-
ing the important role of MRL proteins in cell proliferation.
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SUPPLEMENTAL DATA  
  
Supplemental Figure 1.  Expression of RIAM on melanoma metastases. Five different 
lymph node melanoma metastases were analyzed by immunohistochemistry. Sections were 
stained with the melanoma specific marker HMB-45 (tumor), with anti-RIAM antibodies, or 
with DAPI to visualize nuclei. 
Supplemental Figure 2.  Expression and functional analyses of RIAM in melanoma cells. 
(A) Expression of RIAM on the indicated melanoma cell lines was assessed by immunobloting 
with anti-RIAM antibodies. (B) BLM cells were infected with pLL3.7 or pLL3.7-shRIAM 
vectors, and upon cell sorting based on GFP expression, transfectants were analyzed by flow 
cytometry. (C) Generation and characterization of F8-Luc RIAM knockdown and mock-luc 
transfectants. HEK-293FT packaging cells were co-transfected using lipofectamine (Invitrogen 
Corp.) with pSFG-GFP-Luc vector (a gift from Dr. Vladimir Ponomarev, Memorial Sloan 
Kettering Cancer Center, New York, NY), and vectors coding for gamma-retrovirus proteins 
gag and pol (pNGVL-MLV-gag-pol) and vesiculovirus envelope glycoprotein (pNGVL-VSV-
G) (gifts from Dr. Rafel Delgado, Hospital 12 de Octubre, Madrid, Spain). Conditioned media 
containing viral particles were used to infect BLM cells, which were sorted based on GFP 
expression. Subsequently, selected cells were subjected to in vitro luciferase activity assays to 
assess their luciferase expression (TD20/20 luminometer, Turner Biosystems, Sunnyvale, CA) 
(not shown). This protocol established the parental BLM-luc cells. Viruses from supernatants of 
HEK-293FT cells transfected either with pRetroSuper or with  pRetroSuper-shRIAM (Origene, 
Rockville, MD) vectors were used to infect BLM-luc cells, which upon selection with 
puromycin gave rise to the mock-Luc and F8-Luc transfectants, respectively. These 
transfectants were analyzed by western blotting with anti-RIAM antibodies (top), or subjected 
to invasion assays across Matrigel (bottom). (D) Stable or transient RIAM-silenced transfectants 
were subjected to invasion assays in response to fetal bovine serum (10%).  (E) MV3 melanoma 
cells were transfected with control or siRNA RIAM #2, and transfectants analyzed by western 
blotting for RIAM expression (left), or tested in invasion assays (right). (F) Cells were subjected 
to gelatinolytic zymography to detect MMP-2 or MMP-9, or to western blotting to assess MT1-
MMP expression. ***Invasions were significantly inhibited, p<0.001. 
Supplemental Figure 3. Constitutive active RhoA partially rescues invasion of RIAM-
silenced melanoma cells. Mock-Luc or F8-Luc cells were transfected with RhoA wild type 
(wt) or constitutively active (CA) vectors, and analyzed by immunoblotting using anti-RhoA 
antibodies (left), or subjected to invasion assays (right). ΔΔInvasion of F8-Luc-Rho CA 
transfectants was significantly higher than F8-Luc-Rho wt counterparts, p<0.01. 
Supplemental Figure 4. RIAM localization on melanoma cells, and RIAM co-precipitation 
with talin. BLM cells were transfected with His-tagged RIAM vectors, and transfectants 
attached onto fibronectin were analyzed by confocal microscopy using anti-RIAM or anti-His 
antibodies (A), or subjected to immunoprecipitation and immunoblotting with the indicated 
antibodies (B). Bar: 25 μm. 
Supplemental Figure 5. Talin-β1 integrin association in talin siRNA transfectants.  BLM 
melanoma cells were transfected with talin (sense strand 
GGAGGAAAUAACAGGGACCdTdT), or with control siRNA using X-tremeGENE (Roche 
Diagnostics, Penzberg, Germany), following manufacturer’s instructions. After 48 hr, 
transfectants were analyzed by immunoblotting (right), or subjected to immunoprecipitation 
with control (Ctr) or Lia 1/2.1 anti-β1 antibodies, followed by immunoblotting with anti-talin, 
anti-β1, anti-α4 or anti-PARP antibodies (left). 
Supplemental Figure 6. Anti-β1 15/7 mAb and fibronectin binding to mock and RIAM-
silenced cells. (A) Mock and D11 cells were incubated with CXCL12 (150 ng/ml) or with 
MnCl2 (1 mM), and subsequently subjected to flow cytometry with 15/7 anti-β1 or control 
P3X63 mAb, followed by detection with a rhodamine-conjugated secondary antibody. Numbers 
indicate mean fluoresecence intensity values. (B) Binding of biotin-labelled fibronectin to mock 
and D11 cells. Fibronectin (1 mg/ml in PBS) was biotinylated (EZ-link Sulfo-NHS-LC-LC 
biotin, Pierce, Rockford, IL) at 4 ºC for 2 hr, following manufacturer’s instructions, and 
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subsequently dialyzed against PBS. After detachment and washing, cells were resuspended in 
HBSS 2% FBS, in the absence or presence of MnCl2. Cells were then exposed for the indicated 
times to fibronectin-biotin (20 μg/ml) at 37 ºC, and following a washing step, they were stained 
with streptavidin-Alexa-488 (Molecular Probes) for 30 min at 4 ºC. Finally, cells were washed 
and fluorescence intensity analyzed in a flow cytometer. Data represent mean fluorescence 
intensity values +/-SD (n=4). (C) Analyses of β1 clustering in mock and D11 cells. Cells were 
incubated with the LM534 anti-β1 mAb (Millipore, Billerica, MA), and the adhesion size and 
intensity were extracted from confocal images (top) (n=20 cells) using custom patch 
morphology analysis software (Digital Cell Imaging Laboratories, Belgium). Adhesions were 
detected and segmented automatically using intensity-threshold and watershed-based algorithms 
(bottom). Identical confocal imaging conditions were used for image acquisition and identical 
algorithms were used for adhesion detection to ensure objective comparison of adhesion 
populations. 
Supplemental Figure 7. Lung metastases from mock and RIAM knockdown melanoma 
cells. Melanoma cells isolated from lung metastases and cultured for 6 days were tested by flow 
cytometry for GFP expression (A), or subjected to Matrigel invasion assays (B). 
Supplemental Figure 8. RIAM-silenced melanoma cells have increased susceptibility to 
apoptosis. Rat tail collagen I 3-D gels were generated as described in the Experimental 
Procedures section. Cells were embedded in the gels, and following 48 h they were fixed and 
stained either with DAPI (left) or Hoechst-34580 (Invitrogen, Camarillo, CA) (right). Cells 
were imaged using a Nikon A1R confocal microscope with 60x oil-immersion objectives. 
DAPI-stained nuclei were classified depending on chromatin compactation, while Hoechst-
stained pixels were pink-coloured when saturated.  
 
 
SUPPLEMENTARY MOVIES 
 
1A. Migration of Mock cells on Matrigel. CXCL12 is located on the top reservoir (see 
Methods). Shown is 1 frame/4 min. 
1B. Dots and lines depicting migration of 15 selected mock cells from movie 1A. 
2A. Migration of D11 cells on Matrigel. CXCL12 is located on the top reservoir (see Methods). 
Shown is 1 frame/4 min. 
2B. Dots and lines depicting migration of 15 selected D11 cells from movie 2A. 
3A, B. Dynamics of membrane protrusions of Mock cells during migration on fibronectin. 
Shown is 1 frame/10 min. 
4C, D. Dynamics of membrane protrusions of D11 cells during migration on fibronectin. Shown 
is 1 frame/10 min. 
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